More on ELGX
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Revenue | 52.12M |
| Cost of goods sold | 15.19M |
| Gross profit | 36.93M |
| Research and development | 8.24M |
| Clinical and regulatory affairs | 3.76M |
| Marketing and sales | 26.01M |
| General and administrative | 9.71M |
| Total operating expenses | 48.17M |
| Loss from operations | -11.23M |
| Interest income | 58K |
| Interest expense | -4.08M |
| Gain on sale of equipment | |
| Other expense | 189K |
| Change in fair value of contingent consideration related to acquisition (Note 10) | |
| Total other expense | |
| Net loss | -15.25M |
| Basic and diluted net loss per share | -0.18 |
| Shares used in computing basic and diluted net loss per share | |
Entities mentioned with ELGX
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Piper Jaffray | View Related Stories »
- Trading Radar | View Related Stories »
- After-Hours Movers | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
